The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Conversion of platinum-taxane resistant to sensitive ovarian cancer with a non-platinum-taxane regimen.
Shinichi Tate
No relevant relationships to disclose
Kyoko Nishikimi
No relevant relationships to disclose
Hirokazu Usui
No relevant relationships to disclose
Akira Mitsuhashi
No relevant relationships to disclose
Makio Shozu
No relevant relationships to disclose